Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
about
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PETCAR therapy: the CD19 paradigmThe histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen.Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices.Spatiotemporal temperature distribution and cancer cell death in response to extracellular hyperthermia induced by gold nanorods.Engineered T cells for cancer treatmentIL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.Biology and clinical application of CAR T cells for B cell malignanciesThe future is now: chimeric antigen receptors as new targeted therapies for childhood cancerSuccessful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.The basic principles of chimeric antigen receptor design.CAR-modified T-cell therapy for cancer: an updated review.Transgene delivery using poly(amino ether)-gold nanorod assemblies.Cancer CARtography: charting out a new approach to cancer immunotherapy.Chimeric antigen receptors for T cell immunotherapy: current understanding and future directionsTargeted immunotherapy of cancer with CAR T cells: achievements and challenges.Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.Genetically engineered T cells for the treatment of cancer.CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.The promise and potential pitfalls of chimeric antigen receptors.Targeting tumours with genetically enhanced T lymphocytes.Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.Seatbelts in CAR therapy: How Safe Are CARS?Targeting cytotoxic T lymphocytes for cancer immunotherapy.Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse modelTumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cellsImproving T cell therapy for cancer.Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsHow do CARs work?: Early insights from recent clinical studies targeting CD19.Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.Simultaneous enhancement of photothermal stability and gene delivery efficacy of gold nanorods using polyelectrolytesDesign and development of therapies using chimeric antigen receptor-expressing T cells
P2860
Q24633858-EE2D087B-B099-4B79-BF5D-37122B0E8B19Q28081642-A9CA35AF-B463-47AA-8E69-4DC6C86CE0D7Q30368366-A5F1858F-0865-4A23-A57A-5EA6A3464B5AQ30491961-B3AF824C-1180-4B1E-A59F-E02994CAB7EBQ30533630-EA0DAC8E-7A82-4C03-9AA5-26079E52D584Q33553779-A031399D-0751-418B-A54A-FB742D520EF5Q33578792-29B1824D-8C0B-4C4F-B571-624AAA03AC2DQ33839836-6DEA6D24-431D-4DA8-863E-CFED7B76D678Q33896804-F7734381-60E7-4011-B0E9-7460E47047ADQ33907565-4E9F269A-BCF7-43AD-AEC0-7E0A283146A9Q33993529-505941CA-DB60-49B9-88DB-E512F0FA8B44Q34007762-AD8633C8-146C-4E9A-8E88-1523D468A92BQ34036213-6D386361-F892-4AD1-9C5B-C8E0F28E293FQ34044213-7B8093ED-9972-4648-BBD0-8A6748D925E8Q34101460-3622AFAC-961F-4EC2-9C1E-9F6638821B11Q34139468-5B907038-CDED-4B8C-9A32-7CF5EE49330CQ34248531-D563BF80-CDA4-48DB-A7C9-D4919993B3EBQ34270375-C62EF60E-FF9D-4EC6-9AB5-506DBDDBE0E3Q34292273-88D00F84-D683-4199-9C1E-4AD0937AB81FQ34645898-48D0554E-9305-4974-A677-5F5B02F127D2Q34667972-4C3F4899-2846-4A44-9901-11D44C184A47Q34970378-BE8CB7CC-9F8A-43CE-8DB5-7A683413AF5CQ35037678-F5F03ED4-BA96-4434-9C4E-4ADCCC3CF0E2Q35399334-B47B1E70-405D-4D5A-B334-9C1EBBD651DEQ35506724-D5846A1C-9E58-4006-A448-422993A34F62Q35673845-22C12AD7-5EB8-465B-AA2E-B5831353B39DQ35758285-9C56A313-426F-4B8C-98B4-656EEF5ECDA0Q35818365-830D2686-3B94-4DC6-93AB-5928A09750CAQ35842135-EE367141-F146-4133-A217-678C3E1A9698Q35855097-E05BEC4F-F79A-43F4-814C-03166805F7C4Q35986612-2276BBFC-7FDD-4FB1-8AE6-6B98F8950F38Q36300730-E80095BE-9D6E-4407-9F2D-E99308754993Q36407236-096F84DF-1D8B-4766-8494-1AA8DF4F77CAQ36422280-883AA6D1-C19D-45AA-8F85-AFF4E557386AQ36470354-927C21BB-195D-4865-B0E6-280D94FC7726Q36476104-F81A20C6-8106-4F4B-A903-0494C35DF8AFQ36801106-F424EA5E-A871-4CF2-AE54-8DD82E35A79FQ37372552-0F536FA6-DB32-42EB-8929-C877B14FC346Q37404861-64D07939-2449-4785-B751-7268A92F43C6Q37418289-395BE2AD-5771-419B-9ACC-B725DAA0E488
P2860
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Cancer patient T cells genetic ...... ate-specific membrane antigen.
@en
type
label
Cancer patient T cells genetic ...... ate-specific membrane antigen.
@en
prefLabel
Cancer patient T cells genetic ...... ate-specific membrane antigen.
@en
P2093
P2860
P356
P1433
P1476
Cancer patient T cells genetic ...... ate-specific membrane antigen.
@en
P2093
P2860
P304
P356
10.1038/SJ.NEO.7900018
P577
1999-06-01T00:00:00Z